A/Prof Benjamin Blyth
Honorary (Principal Fellow)
The Sir Peter MacCallum Department of Oncology
97 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Abstract PS4-04-08: Radioimmunotherapy using 64/67Copper labelled trastuzumab in mice bearing HER2-positve xenografts as a model for breast cancer therapy
DOI: 10.1158/1557-3265.sabcs25-ps4-04-082026
Journal article
Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting
DOI: 10.1039/d6ra90008a2026
Journal article
Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting
DOI: 10.1039/d5ra08789a2026
Journal article
Carbonic Anhydrase-IX Is a Specific and Sensitive Theragnostic Target for Imaging and Radioimmunotherapy in Metastatic Colorectal Cancer
DOI: 10.1016/j.gastha.2025.1008712025
Other
Figure S5 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
DOI: 10.1158/2159-8290.308696182025
Other
Figure S7 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
DOI: 10.1158/2159-8290.308696122022
Research grants (other domestic)
Investigating a New Strategy for Diagnosis and Personalised Treatment of Hormone Positive Metastatic Breast Cancer Using Dual Purpose Theranostics Targeting the Neuropeptide Y-1 Receptor
RECENT SCHOLARLY WORKS
2025
Other
Table S2 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
DOI: 10.1158/2159-8290.308696062025
Other
Figure S3 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
DOI: 10.1158/2159-8290.308696242025
Other
Table S1 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
DOI: 10.1158/2159-8290.308696092025
Other
Figure S6 from Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity
DOI: 10.1158/2159-8290.30869615